Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO and TEL AVIV, Israel, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) is pleased to announce the closing of the first tranche of its private placement, for 10,946,...
SAN FRANCISCO and TEL AVIV, Israel, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it is updating the terms of its private placement previously announced on August 21, 2019 (the ȁ...
SAN FRANCISCO and TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has elected to make an interest payment under the C$787,500 principal amount secured convertible d...
Kalytera Therapeutics ( OTCQB:KALTF ): Q2 GAAP EPS of -$0.01. More news on: Kalytera Therapeutics, Inc., Earnings news and commentary, Energy stocks news, , Read more ...
SAN FRANCISCO and TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today reported financial results for the second quarter of 2019. (All dollars U.S. unless otherwise noted.) “Kaly...
About a month ago I wrote an article summarizing the investment opportunities and risks with Kalytera Therapeutics, Inc. ( KALTF ) (KLY.V). Since then, the company has released stunning Phase 2 clinical study data evaluating cannabidiol, or CBD, for the prevention of acute graft versus hos...
SAN FRANCISCO and TEL AVIV, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it intends to raise up to approximately CDN $1.5 million (USD $1.13 million) in a private placement (t...
SAN FRANCISCO and TEL AVIV, Israel, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“ CBD ...
The growth of the cannabis industry has made it possible for companies to offer investment opportunities through the major listing exchanges in Canada. Previously known as the Canadian Venture Exchange, the TSX Venture Exchange is the sibling listing to the larger Toronto Stock Exchange...
SAN FRANCISCO and TEL AVIV, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) announced today that shareholder votes on the election of directors, the approval of the Compan...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...